Crossmark

Multiple sclerosis patients taking glucagon-like peptide-1 receptor (GLP-1) agonists: a single-institution retrospective cohort study of tolerability and weight loss

Crossref DOI link: https://doi.org/10.1007/s10072-024-07701-7

Published Online: 2024-07-20

Published Print: 2025-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Udawatta, Methma

Fidalgo, Nicholas

Mateen, Farrah J. https://orcid.org/0000-0002-4293-8115
License Information

Text and Data Mining valid from 2024-07-20

Version of Record valid from 2024-07-20
More Information

Article History

Received: 15 March 2024

Accepted: 12 July 2024

First Online: 20 July 2024

Ethics approval and reporting guidelines

: This retrospective cohort study protocol was approved by the Mass General Brigham Institutional Review Board. Reporting of the study protocol follows the STROBE guidelines. []

: F. Mateen has received research funding from EMD Serono, Genentech, Horizon Therapeutics, Novartis, and TG Therapeutics, and has consulted for Alexion, EMD Serono, Genentech, and Horizon Therapeutics, all unrelated to this work. M. Udawatta and N. Fidalgo received no specific grants from any funding agency in the public, commercial, or not-for-profit sectors.

Document is current

Any future updates will be listed below